Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...

Salarius Pharmaceuticals (SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating ...

Tamil Nadu Congress Committee President K Selvaperunthagai on Saturday hit out at the Union Budget as "brazenly partial" and "anti-farmer". The Budget was hugely disappointing as it was "anti-farmers" ...

Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients ...

Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its ...